Late recurrences of atrial fibrillation in patients after direct-current cardioversion

Czech version

Authors: M. Gurčiková; J. Kalužay; S. Remišová; O. Jurkovičová; P. Ponťuch
Authors‘ workplace: IV. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. Peter Ponťuch, CSc.
Published in: Vnitř Lék 2008; 54(6): 604-608
Category: Original Contributions

Overview

Aim:
To analyze factors after successful direct-current cardioversion in patients with atrial fibrillation and to explore late recurrences of the arrhythmia.

Methods:
Forty-three patients with atrial fibrillation without associated valvular heart disease, who underwent non-emergent cardioversion within the years 2002-2006, were included. We retrospectively analyzed clinical data from the medical records. Late reccurence of the arrhythmia was defined as arrhythmia in patients discharged with sinus rhythm.

Results:
Median follow-up of the patients was 33 [17, 48] months. We found 20 late recurrences of atrial fibrillation in the total group of 43 patients after successful direct-current cardioversion (46.5%). In a 6-month period after direct-current cardioversion the recurrence of arrhythmia was found in two patients, in a one-year period in 6 patients and in a period longer than one year in 12 patients. Median time to recurrence was 15 [6, 33] months. Females relapsed more frequently than males (p < 0.02), what could be explained by higher age, incidence of hypertension and thyreopathy in females. Patients with a history of thyropathy had more frequent occurrence of arrhythmia, despite normal values of TSH, as compared to patients without a history of thyropathy (p < 0.04). Patients with recurrence of the atrial fibrillation had higher systolic pressure (130 vs 120 mm Hg, p < 0.05) and pulse arterial pressure (50 vs 40 mm Hg, p < 0.01) after cardioversion. No significant difference between the two groups in age, left atrium diameter, left ventricle ejection fraction and cardiovascular, or non-cardiovascular risk factors was found.

Conclusion:
Despite successful direct-current cardioversion, the risk of late recurrence of the atrial fibrillation in a following period is at least 46.5%. Females, patients with a history of thyropathy and those with higher systolic and pulse arterial pressures are at higher risk of late recurrences.

Key words:
atrial fibrillation - direct-current cardioversion - late recurrences of atrial fibrillation

Sources

1. Friberg J, Buch P, Scharling H et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: 666-672.

2. Frick M, Frykman V, Jensen-Urstad M et al. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001; 24: 238-244.

3. Blich M, Edoute Y. Electrical cardioversion for persistent or chronic atrial fibrillation: outcome and clinical factors predicting short and long term success rate. Int J Cardiol 2006; 107: 389-394.

4. Fetsch T, Bauer P, Engberding R et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385-1394.

5. Page RL, Tilsch TW, Connolly SJ et al. Asymptomatic or “silent” atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation 2003; 107: 1141-1145.

6. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844.

7. Katritsis DG, Toumpoulis IK, Giazitzoglou E et al. Latent arterial hypertension in apparently lone atrial fibrillation. J Interv Card Electrophysiol 2005; 13: 203-207.

8. Mitchell GF, Vasan RS, Keyes MJ et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007; 297: 709-715.

9. Humphries KH, Kerr CR, Connolly SJ et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001; 103: 2365-2370.

10. Gurevitz OT, Varadachari CJ, Ammash NM et al. The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion. Am Heart J 2006; 152: 155.

11. Van Noord T, Tieleman RG, Bosker HA et al. Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 2004; 6: 343-350.

12. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098.

13. Madrid AH, Peng J, Zamora J et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004; 27: 1405-1410.

14. Yin Y, Dalal D, Liu Z et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27: 1841-1846.

15. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.

16. Hirayama Y, Atarashi H, Kobayashi Y et al. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J 2005; 69: 671-676.

17. Gammage MD, Parle JV, Holder RL et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007; 167: 928-934.

18. Hrnciar J. Thyrotoxic heart disease. Part II - aspects of treatment of thyrotoxicosis with cardiac involvement. Vnitř Lék 2002; 48: 137-141.

19. Murphy NF, Stewart S, MacIntyre K et al. Seasonal variation in morbidity and mortality related to atrial fibrillation. Int J Cardiol 2004; 97: 283-288.

20. Sojo L, Corcoy R. Seasonal variation in morbidity and mortality related to atrial fibrillation - could thyroid function contribute? Int J Cardiol 2006; 107: 281.

21. Olshansky B, Heller EN, Mitchell LB et al. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol 2005; 45: 2026-2033.

22. Schotten U, de Haan S, Neuberger HR et al. Loss of atrial contractility is primary cause of atrial dilatation during first days of atrial fibrillation. Am J Physiol Heart Circ Physiol 2004; 287: H2324-H2331.